Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of America Corp (BAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of America Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Bank of America Corp trades at $64.06 (market cap $446.56B). The key difference: Bank of America Corp is far larger — about 516.9× Amphastar Pharmaceuticals Inc's market cap, and Bank of America Corp pays a 2% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BAC | |
|---|---|---|
Market Cap | $863.95M | $446.56B |
Sector | Health | Financials |
52-Week High | $30.81 | $64.00 |
52-Week Low | $16.87 | $46.72 |
Enterprise Value | $1.26B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
